NCT06403202 Prognostic Performance of a Chemogram in Patients With Bladder Cancer.
| NCT ID | NCT06403202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lille Catholic University |
| Condition | Urinary Bladder Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-08-23 |
| Primary Completion | 2024-08-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of the study is to evaluate chemogram in patients with intermediate-grade superficial bladder cancer and patients with infiltrating bladder cancer, who are likely to be treated according to the standard procedure. This project is based on the premise that treatments - notably chemotherapy - are standard, but that each cancer is unique. It is therefore necessary to personalize the treatment for each patient, while at the same time proposing an approach that is economically bearable for the healthcare system. For both types of bladder tumor, chemotherapy is used either as an alternative to immunotherapy, or as an adjuvant to surgery. Its use is therefore based on its effectiveness in reducing post-treatment recurrence.
Eligibility Criteria
Inclusion Criteria: * Major patient * Patient with suspected bladder cancer likely to be treated with chemotherapy * Patient affiliated to a social security scheme Exclusion Criteria: * Insufficient tumor volume * Patient under guardianship * Pregnant or breast-feeding women * Patient opposed to participation in the study